A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Melanoma

Study type: Observational

Funder types: Industry

Identifiers

NCT05115006

CA209-8YR

Details and patient eligibility

About

The purpose of this study is to understand the trade-offs that participants with surgically treated melanoma would be willing to make among key features and outcomes of adjuvant anti-cancer treatments or no adjuvant treatment / observation.

Enrollment: 294 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Self-reported medical diagnosis of stage II or stage III melanoma
• Have been resected (had surgery) for their melanoma within 12 months prior to study participation

Exclusion criteria

• Self-reported stage IIa
• Self-reported recurrence of melanoma after surgery

Other protocol-defined inclusion/exclusion criteria apply

Trial design

294 participants in 1 patient group

Cohort 1

Description:

Participants diagnosed with stage II and stage III melanoma who have undergone surgery